scholarly journals Treatment of Advanced Basal Cell Carcinoma with Hedgehog Pathway Inhibitors: A Multidisciplinary Expert Meeting

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5706
Author(s):  
Vincenzo De Giorgi ◽  
Federica Scarfì ◽  
Luciana Trane ◽  
Flavia Silvestri ◽  
Federico Venturi ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Real World ◽  
Clinical Guidelines ◽  
Recent Progress ◽  
Hedgehog Pathway ◽  
Expert Meeting ◽  
Advanced Basal Cell Carcinoma

Despite recent progress and the publishing of several clinical guidelines on the management of advanced basal cell carcinoma, there is still no comprehensive set of clinical guidelines addressing the complexity inherent to the use of Hedgehog pathway inhibitors in the treatment of advanced basal cell carcinoma in real-world clinical practice. To develop practical and valuable tools that help specialists improve the clinical management of these patients, we sought the opinion of expert physicians with extensive knowledge and experience in the treatment of advanced basal cell carcinoma.

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

2009 ◽  
Vol 361 (12) ◽  
pp. 1164-1172 ◽  
Author(s):  
Daniel D. Von Hoff ◽  
Patricia M. LoRusso ◽  
Charles M. Rudin ◽  
Josina C. Reddy ◽  
Robert L. Yauch ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Hedgehog Pathway ◽  
Advanced Basal Cell Carcinoma

scholarly journals A Practical Guide for the Follow‐Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors

2019 ◽  
Vol 24 (8) ◽  
Author(s):  
Clio Dessinioti ◽  
Mikaella Plaka ◽  
Efthymia Soura ◽  
Despoina Mortaki ◽  
George Papaxoinis ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Hedgehog Pathway ◽  
Practical Guide ◽  
Advanced Basal Cell Carcinoma

scholarly journals Characterization and Management of Hedgehog Pathway Inhibitor‐Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

2016 ◽  
Vol 21 (10) ◽  
pp. 1218-1229 ◽  
Author(s):  
Mario E. Lacouture ◽  
Brigitte Dréno ◽  
Paolo Antonio Ascierto ◽  
Reinhard Dummer ◽  
Nicole Basset‐Seguin ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Hedgehog Pathway ◽  
Hedgehog Pathway Inhibitor ◽  
Advanced Basal Cell Carcinoma

scholarly journals Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib

2014 ◽  
Vol 70 (1) ◽  
pp. 60-69 ◽  
Author(s):  
Anne Lynn S. Chang ◽  
James A. Solomon ◽  
John D. Hainsworth ◽  
Leonard Goldberg ◽  
Edward McKenna ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Hedgehog Pathway ◽  
Expanded Access ◽  
Hedgehog Pathway Inhibitor ◽  
Advanced Basal Cell Carcinoma

scholarly journals Treatment of periocular advanced basal cell carcinoma with Hedgehog pathway inhibitors: a single-center study and a new dedicated therapeutic protocol

2021 ◽  
Author(s):  
Vincenzo De Giorgi ◽  
Luciana Trane ◽  
Giulia Pieretti ◽  
Nicola Santoro ◽  
Flavia Silvestri ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Locally Advanced ◽  
Delayed Diagnosis ◽  
Case Series ◽  
Hedgehog Pathway ◽  
Single Center ◽  
Management Protocol ◽  
Advanced Basal Cell Carcinoma

Background: The management of difficult-to-treat periocular basal cell carcinoma becomes very challenging in cases of delayed diagnosis, leading to the development of locally advanced basal cell carcinoma.Objective: The aim of this study was to evaluate the outcomes of Hedgehog pathway inhibitors (vismodegib and sonidegib)  treatment in patients affected by periocular locally advanced basal cell carcinoma. We focused on the common adverse events  and their correlation with the administration schedule  in order to determine a management protocol specific for the periocular area.Methods:  This observational prospective study included a single-center case series with patients who were histologically confirmed to have periocular or orbital locally advanced basal cell carcinoma,  treated with Hedgehog pathway inhibitors.Results: All patients benefitted in terms of regression or stabilization of the neoplasm. In the first months of treatment, the HPIs were well tolerated, and the first important side effects appeared after about 5 months of continuous use of the drug.Conclusion: These data could lead to a new type of therapeutic scheme where neoadjuvant therapy could be followed by pulse therapy as an adjuvant to surgery.

scholarly journals Vismodegib for giant, locally advanced, basal cell carcinoma and its complex position in clinical practice

2019 ◽  
Vol 5 (3) ◽  
pp. 267-270
Author(s):  
Fabiënne H.J. Koekelkoren ◽  
Sofie L. Roodbergen ◽  
Ewout M. Baerveldt ◽  
Alexander P.W.M. Maat ◽  
Dominiek A. Monserez ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Locally Advanced ◽  
Advanced Basal Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document